UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen

Oncology

Volumn 72, Issue 5-6, 2007, Pages 267-273

  Scalamogna, R ^a   Brugnatelli, S ^a   Tinelli, C ^b   Sagrada, P ^a   Gattoni, E ^a   Tronconi, M C ^a   Riccardi, A ^a   Luchena, G ^c   Corazza, G R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c SANT ANNA HOSPITAL   (Italy)

Author keywords

5 Fluorouracil; FOLFOX4; Metastatic colorectal cancer; Oral chemotherapy; Oxaliplatin; Quality of life; SF 36 questionnaire; UFT

Indexed keywords

CETUXIMAB; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TROPISETRON; UFT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISTRESS SYNDROME; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; MAINTENANCE THERAPY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 39049164561     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113037     Document Type: Article

References (27)

1. Gatta G, Faivre J, Capocaccia R, et al: Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 1998;34:2176-2183.
2. Steele GD Jr: The National Cancer Data Base report on colorectal cancer. Cancer 1994;74:1979-1989.
3. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma (review). J Clin Oncol 1989;7:1407-1418.
4. NHS Executive: Recurrent and advanced disease;in: Improving Outcomes in Colorectal Cancer: The Research Evidence. CCO1200. London, Stationery Office, 1997, pp 98-125.
5. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
6. Gamelin E, Gamelin L, Bossi L, Quasthoff S: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002;29(suppl 15):21-33.
7. Grothey A: Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;30(suppl 15):5-13.
8. Tournigand C, Cervantes A, Figer A, et al: Optimox1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006;24:394-400.
9. Ito K, Kato T, Koike A, et al: Optimum duration of oral adjuvant chemotherapy of HCFU for colorectal cancer: review of 5-year follow-up. Anticancer Res 2000;20:4681-4686.
10. Au JL, Wu AT, Friedman MA, Sadee W: Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep 1979;63:343-350.
11. El Sayed YM, Sadee W: Metabolic activation of R,S-1-(tetrahydro-2- furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes. Cancer Res 1983;43:4039-4044.
12. Ho DH, Covington WP, Pazdur R, et al: Clinical pharmacology of combined oral uracil and ftorafur. Drug Metab Dispos 1992;20:936-940.
13. Pazdur R, Lassere Y, Diazcanton E, Bready B, Ho DH: Phase I trial of uracil-tegafur (UFT) plus oral leucovorin - 14-day schedule. Invest New Drugs 1997;15:123-128.
14. Meropol NJ, Rustum YM, Petrelli NJ, et al: A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 1996;37:581-586.
15. Pazdur R, Lassere Y, Diaz-Canton E, Bready B, Ho DH: Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs 1996;7:728-733.
16. Muggia FM, Wu XY, Spicer D, et al: Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res 1996;2:1461-1467.
17. Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296-2300.
18. Saltz LB, Leichman CG, Young CW, et al: A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995;75:782-785.
19. Gonzales-Baron M, Feliu J, de la Gandara I, et al: Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 1995;31A:2215-2219.
20. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988;22:333-338.
21. Douillard J-Y, Hoff PM, Skilling JR, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-3616.
22. Carmichael J, Popiela T, Radstone D, et al: Randomized comparative study of tegafur/ uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-3627.
23. Ware JE, Sherbourne CD: The MOS 36-item Short Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
24. Apolone G, Moscone P: The Italian SF-36 Health Survey translation, validation and norming. J Clin Epidemiol 1998;51:1025-1036.
25. Ware J, Snow K, Kosinski M, et al: SF-36 Health Survey manual and interpretation guide. Boston, Health Institute, New England Medical Center, 1993.
26. de Gramont A, Vigoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-219.
27. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS: Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66:3386-3391.